HUE046617T2 - Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok - Google Patents

Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok

Info

Publication number
HUE046617T2
HUE046617T2 HUE16180927A HUE16180927A HUE046617T2 HU E046617 T2 HUE046617 T2 HU E046617T2 HU E16180927 A HUE16180927 A HU E16180927A HU E16180927 A HUE16180927 A HU E16180927A HU E046617 T2 HUE046617 T2 HU E046617T2
Authority
HU
Hungary
Prior art keywords
lrrk2
modulators
aminopyrimidine derivatives
pyrazole
pyrazole aminopyrimidine
Prior art date
Application number
HUE16180927A
Other languages
English (en)
Hungarian (hu)
Inventor
Charles Baker-Glenn
Daniel Jon Burdick
Mark Chambers
Huifen Chen
Anthony Estrada
Zachary Kevin Sweeney
Bryan K Chan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HUE046617T2 publication Critical patent/HUE046617T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE16180927A 2010-11-10 2011-11-09 Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok HUE046617T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41227310P 2010-11-10 2010-11-10
US201161546613P 2011-10-13 2011-10-13

Publications (1)

Publication Number Publication Date
HUE046617T2 true HUE046617T2 (hu) 2020-03-30

Family

ID=44983512

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16180927A HUE046617T2 (hu) 2010-11-10 2011-11-09 Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
HUE11782588A HUE037844T2 (hu) 2010-11-10 2011-11-09 Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE11782588A HUE037844T2 (hu) 2010-11-10 2011-11-09 Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok

Country Status (28)

Country Link
US (1) US8815882B2 (2)
EP (3) EP3124483B1 (2)
JP (3) JP5986094B2 (2)
KR (1) KR101566091B1 (2)
CN (1) CN103313978B (2)
AR (1) AR083813A1 (2)
AU (1) AU2011328139A1 (2)
BR (1) BR112013011600B1 (2)
CA (2) CA2812669C (2)
CY (1) CY1120073T1 (2)
DK (2) DK2638031T3 (2)
EC (1) ECSP13012611A (2)
ES (2) ES2653967T3 (2)
HR (2) HRP20172006T1 (2)
HU (2) HUE046617T2 (2)
IL (1) IL225234A0 (2)
LT (2) LT3124483T (2)
MA (1) MA34644B1 (2)
MX (1) MX2013005199A (2)
NO (1) NO2638031T3 (2)
PH (1) PH12013500880A1 (2)
PL (2) PL2638031T3 (2)
PT (2) PT3124483T (2)
RS (2) RS59106B1 (2)
SG (1) SG189043A1 (2)
SI (2) SI2638031T1 (2)
TW (1) TW201302733A (2)
WO (1) WO2012062783A1 (2)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2637936C2 (ru) 2011-05-23 2017-12-08 Элан Фармасьютикалз, Инк. Ингибиторы активности киназы lrrk2
MX348920B (es) * 2011-11-29 2017-07-04 Genentech Inc Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
US20140228384A1 (en) * 2011-11-29 2014-08-14 Genentech, Inc. Assays and biomarkers for lrrk2
KR102012057B1 (ko) * 2011-11-29 2019-08-19 제넨테크, 인크. Lrrk2 조절제로서 아미노피리미딘 유도체
US9145402B2 (en) 2011-11-29 2015-09-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
EP2785381B1 (en) * 2011-11-30 2016-05-18 F.Hoffmann-La Roche Ag Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2
KR102091895B1 (ko) * 2012-05-03 2020-04-14 제넨테크, 인크. 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
EP2844652B1 (en) * 2012-05-03 2019-03-13 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
ES2665148T3 (es) 2013-12-17 2018-04-24 Merck Patent Gmbh Derivados de N1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piperidina como inhibidores de la piruvato deshidrogenasa quinasa
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US9556126B2 (en) 2013-12-20 2017-01-31 Signal Pharmaceuticals, Llc Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
RU2016134751A (ru) 2014-01-29 2018-03-02 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
MA39219B1 (fr) * 2014-01-29 2018-11-30 Glaxosmithkline Ip Dev Ltd Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
WO2015148867A1 (en) * 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
AU2015201630A1 (en) * 2014-03-31 2015-10-15 Commonwealth Scientific And Industrial Research Organisation Diamine compounds for phosphorescent diazaborole metal complexes and electroluminescent devices
GB2538476B (en) 2014-05-08 2019-03-20 Tosoh F Tech Inc 5-(Trifluoromethyl)pyrimidine derivatives and method for producing same
US10058559B2 (en) 2014-05-15 2018-08-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment or prevention of an intestinal disease or disorder
JP6262079B2 (ja) * 2014-06-02 2018-01-17 東ソー・ファインケム株式会社 4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
JP6431294B2 (ja) * 2014-06-16 2018-11-28 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体及びその製造法
WO2016060963A1 (en) 2014-10-14 2016-04-21 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
US11026936B2 (en) 2016-03-29 2021-06-08 Merck Patent Gmbh Piperidinyl-propanone derivatives
CN109071490B (zh) 2016-04-28 2021-04-06 默克专利股份公司 哌啶基衍生物
SMT202100699T1 (it) * 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
KR101923852B1 (ko) 2017-02-24 2018-11-29 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
WO2018217946A1 (en) * 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods
AU2018294254C1 (en) * 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
AR112392A1 (es) * 2017-07-14 2019-10-23 Glaxosmithkline Ip Dev Ltd Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
EP3717473B1 (en) 2017-11-21 2024-01-10 Denali Therapeutics Inc. Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
CN112088003B (zh) * 2017-12-20 2023-10-13 戴纳立制药公司 制备嘧啶基-4-氨基吡唑化合物的工艺
WO2019160037A1 (ja) * 2018-02-14 2019-08-22 国立大学法人 東京大学 酸ハロゲン化物による化合物の製造方法
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AR118641A1 (es) * 2019-04-11 2021-10-20 Denali Therapeutics Inc Compuestos, composiciones y métodos
US11518758B2 (en) * 2019-05-10 2022-12-06 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
JP7714473B2 (ja) * 2019-05-31 2025-07-29 デナリ セラピューティクス インコーポレイテッド ピリミジニルアミノピラゾール化合物の調節放出製剤および処置方法
CN110627810B (zh) * 2019-06-05 2024-05-10 中国医学科学院药用植物研究所 一种三氟甲基吡唑衍生物的制备方法
PE20221083A1 (es) 2019-06-17 2022-07-05 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
AU2020311940A1 (en) * 2019-07-11 2022-02-03 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
US20230131830A1 (en) * 2020-03-06 2023-04-27 National Health Research Institutes Pyrimidine compounds and their pharmaceutical uses
KR102342803B1 (ko) 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
AU2021243887A1 (en) 2020-03-23 2022-11-03 Korea Research Institute Of Chemical Technology Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
EP4236950A4 (en) 2020-10-29 2024-10-23 Merck Sharp & Dohme LLC N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk﹘5抑制劑和彼之用途
US20240174679A1 (en) * 2021-03-17 2024-05-30 Merck Sharp & Dohme Llc Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
JP2024512024A (ja) * 2021-03-23 2024-03-18 ハリア・セラピューティクス・インコーポレイテッド Lrrk2キナーゼ阻害剤として有用なピリミジン誘導体
CN117355304A (zh) * 2021-03-26 2024-01-05 住友制药肿瘤公司 Alk-5抑制剂及其用途
AU2022243600A1 (en) * 2021-03-26 2023-10-12 Sumitomo Pharma Oncology, Inc. Alk-5 inhibitors and uses thereof
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023174946A1 (en) 2022-03-15 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Early and non-invasive method for assessing a subject's risk of having parkinson's disease
EP4525875A1 (en) * 2022-05-20 2025-03-26 Merck Sharp & Dohme LLC Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
TW202434570A (zh) 2022-11-03 2024-09-01 美商戴納立製藥公司 嘧啶三唑化合物之固體及共晶體形式
CN120659780A (zh) 2022-11-22 2025-09-16 戴纳立制药公司 嘧啶氨基吡唑化合物的制备方法和中间体
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用
CN118546132A (zh) * 2023-02-27 2024-08-27 科辉智药(深圳)新药研究中心有限公司 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用
WO2025051214A1 (zh) * 2023-09-07 2025-03-13 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法
WO2025235687A1 (en) * 2024-05-08 2025-11-13 Brenig Therapeutics, Inc. Lrrk2 inhibitors

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9407799A (pt) 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
KR100643419B1 (ko) 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Hiv를 억제하는 피리미딘 유도체
US6458823B1 (en) 1998-06-08 2002-10-01 Wyeth Diaminopyrazoles
US6172222B1 (en) 1998-06-08 2001-01-09 American Home Products Corporation Diaminopyrazoles
SK287270B6 (sk) 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
BR0013551A (pt) 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
TR200200763T2 (tr) 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
AU783981C (en) 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ATE407132T1 (de) 2000-12-05 2008-09-15 Vertex Pharma Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116452A (pt) 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
WO2002092573A2 (en) 2001-05-16 2002-11-21 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
BR0209774A (pt) 2001-05-29 2004-06-01 Schering Ag Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
AU2002315388A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
AU2002316421B2 (en) 2001-06-26 2008-05-15 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-ALPHA expression
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
ATE407678T1 (de) 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
WO2003055489A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
EP1483260A1 (de) * 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
JP2006508997A (ja) 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Chk−、Pdk−およびAkt−阻害性ピリミジン、それらの製造および薬剤としての使用
US20040242613A1 (en) 2003-01-30 2004-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
WO2004103975A1 (de) 2003-05-21 2004-12-02 Bayer Cropscience Aktiengesellschaft Iodpyrazolylcarboxanilide
CA2531490A1 (en) 2003-07-15 2005-02-03 Neurogen Corporation Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands
JP2007500178A (ja) 2003-07-30 2007-01-11 サイクラセル・リミテッド プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
WO2005012294A1 (en) * 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
ATE506953T1 (de) 2003-08-07 2011-05-15 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
JP2008505910A (ja) 2004-07-08 2008-02-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Pkc−シータのインヒビターとして有用なピリミジン誘導体
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
JP2008511659A (ja) 2004-09-01 2008-04-17 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4−ピリミジンジアミン化合物の合成
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
MX2007007272A (es) 2004-12-17 2007-07-11 Astrazeneca Ab 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
DE102005008310A1 (de) 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
EP1705177A1 (en) 2005-03-23 2006-09-27 Schering Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
CN101218229A (zh) * 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
JP2008543855A (ja) 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ, インコーポレイテッド 変形性骨疾患を処置するための方法および組成物
NZ564222A (en) 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
AU2006287767B2 (en) 2005-09-07 2010-05-13 Merck Serono Sa IKK inhibitors for the treatment of endometriosis
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
PE20120006A1 (es) 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
RU2008152193A (ru) 2006-06-15 2010-07-20 Бёрингер Ингельхайм Интернациональ Гмбх (De) 2-амино-4-аминоалкиленаминопиримидины
US20080131937A1 (en) 2006-06-22 2008-06-05 Applera Corporation Conversion of Target Specific Amplification to Universal Sequencing
EP2059512A1 (en) 2006-08-01 2009-05-20 Praecis Pharmaceuticals Incorporated P38 kinase inhibitors
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
US20080194575A1 (en) 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
EP2139482B1 (en) 2006-11-27 2011-11-16 Ares Trading S.A. Treatment for multiple myeloma
EA017405B9 (ru) 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
CN101563327A (zh) 2006-12-19 2009-10-21 健泰科生物技术公司 嘧啶类激酶抑制剂
EP1939185A1 (de) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
WO2008077885A2 (en) 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
KR20100020454A (ko) 2007-06-08 2010-02-22 바이엘 크롭사이언스 소시에떼아노님 살진균제 헤테로사이클릴-피리미디닐-아미노 유도체
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
PL2205603T3 (pl) 2007-09-28 2014-07-31 Cyclacel Ltd Pochodne pirymidyny jako inhibitory kinaz białkowych
US8058279B2 (en) 2007-10-09 2011-11-15 Dow Agrosciences Llc Insecticidal pyrimidinyl aryl hyrdrazones
UA104849C2 (uk) 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
US8461147B2 (en) 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
CA2707989A1 (en) 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
WO2009127642A2 (en) * 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
JP5798481B2 (ja) 2008-06-25 2015-10-21 エジソン ファーマシューティカルズ, インコーポレイテッド 酸化ストレス疾患を治療するための2−ヘテロシクリルアミノアルキル−(p−キノン)誘導体
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2729045A1 (en) 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
JP5644499B2 (ja) 2008-09-01 2014-12-24 アステラス製薬株式会社 2,4−ジアミノピリミジン化合物
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
KR20110049905A (ko) 2008-09-03 2011-05-12 바이엘 크롭사이언스 아게 4-알킬-치환된 디아미노피리미딘
US20100144722A1 (en) 2008-09-03 2010-06-10 Dr. Reddy's Laboratories Ltd. Novel heterocyclic compounds as gata modulators
EA201100436A1 (ru) 2008-09-03 2011-10-31 Байер Кропсайенс Аг Гетероциклически замещенные анилинопиримидины в качестве фунгицидов
KR20110058864A (ko) 2008-09-03 2011-06-01 바이엘 크롭사이언스 아게 살진균제로서의 헤테로사이클 치환된 아닐리노피리미딘
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP3828185B1 (en) 2009-01-06 2024-11-20 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
US20110071158A1 (en) 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
AU2010231694A1 (en) * 2009-03-30 2011-10-06 Astellas Pharma Inc. Pyrimidine compound
CA2758614A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CA2763717A1 (en) 2009-06-10 2010-12-16 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
EP2440548A1 (en) * 2009-06-10 2012-04-18 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
EP2443106A1 (en) 2009-06-18 2012-04-25 Cellzome Limited Heterocyclylaminopyrimidines as kinase inhibitors
CA2763720A1 (en) 2009-06-18 2010-12-23 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
JP5752691B2 (ja) 2009-09-29 2015-07-22 グラクソ グループ リミテッドGlaxo Group Limited 新規化合物
EA024729B1 (ru) 2009-11-13 2016-10-31 Джиноско Киназные ингибиторы
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US8470820B2 (en) 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
ES2577829T3 (es) * 2010-06-04 2016-07-19 F. Hoffmann-La Roche Ag Derivados de aminopirimidina como moduladores de la LRRK2
MX348920B (es) * 2011-11-29 2017-07-04 Genentech Inc Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
US9145402B2 (en) * 2011-11-29 2015-09-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
KR102012057B1 (ko) * 2011-11-29 2019-08-19 제넨테크, 인크. Lrrk2 조절제로서 아미노피리미딘 유도체
EP2785381B1 (en) * 2011-11-30 2016-05-18 F.Hoffmann-La Roche Ag Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2

Also Published As

Publication number Publication date
RS56583B1 (sr) 2018-02-28
CA2812669C (en) 2018-11-06
ES2653967T3 (es) 2018-02-09
US8815882B2 (en) 2014-08-26
EP3590933A1 (en) 2020-01-08
SI3124483T1 (sl) 2019-10-30
AR083813A1 (es) 2013-03-27
PH12013500880A1 (en) 2013-07-01
JP6298115B2 (ja) 2018-03-20
EP2638031A1 (en) 2013-09-18
JP2018109038A (ja) 2018-07-12
LT3124483T (lt) 2019-09-25
IL225234A0 (en) 2013-06-27
JP5986094B2 (ja) 2016-09-06
HRP20172006T1 (hr) 2018-02-09
EP3590933B1 (en) 2021-01-06
EP3124483A1 (en) 2017-02-01
KR20130093657A (ko) 2013-08-22
CY1120073T1 (el) 2018-12-12
ES2746134T3 (es) 2020-03-04
JP2013545741A (ja) 2013-12-26
WO2012062783A1 (en) 2012-05-18
CA2812669A1 (en) 2012-05-18
TW201302733A (zh) 2013-01-16
RS59106B1 (sr) 2019-09-30
EP3124483B1 (en) 2019-07-10
PT2638031T (pt) 2018-01-03
DK2638031T3 (en) 2017-12-11
NO2638031T3 (2) 2018-03-10
PL3124483T3 (pl) 2020-03-31
JP2017008074A (ja) 2017-01-12
LT2638031T (lt) 2017-12-11
BR112013011600A8 (pt) 2021-09-08
CA3017869A1 (en) 2012-05-18
CN103313978B (zh) 2015-04-15
BR112013011600B1 (pt) 2022-01-11
HRP20191781T1 (hr) 2019-12-27
HK1187605A1 (en) 2014-04-11
AU2011328139A1 (en) 2013-04-04
DK3124483T3 (da) 2019-09-02
JP6524284B2 (ja) 2019-06-05
HUE037844T2 (hu) 2018-09-28
MA34644B1 (fr) 2013-11-02
SI2638031T1 (en) 2018-02-28
EP2638031B1 (en) 2017-10-11
EP2638031B9 (en) 2020-01-08
MX2013005199A (es) 2013-06-28
BR112013011600A2 (pt) 2016-08-09
US20120157427A1 (en) 2012-06-21
CN103313978A (zh) 2013-09-18
ECSP13012611A (es) 2013-07-31
CA3017869C (en) 2021-07-27
PT3124483T (pt) 2019-10-02
KR101566091B1 (ko) 2015-11-04
PL2638031T3 (pl) 2018-03-30
SG189043A1 (en) 2013-05-31

Similar Documents

Publication Publication Date Title
HUE046617T2 (hu) Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
ZA201208589B (en) Aminopyrimidine derivatives as lrrk2 modulators
HUS1900001I1 (hu) Transztiretin expressziójának módosítása
IL236407A (en) Heterocyclic modulators for lipid synthesis
IL223962B (en) Modulation of dystrophia myotonica-protein kinase(dmpk) expression
DK2411397T3 (da) Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
ZA201306655B (en) Heterocyclic modulators of lipid synthesis
DK2590974T3 (da) Tetrahydropyridopyrimidinderivater
CO6801764A2 (es) Derivados de pirazol
SG2014009260A (en) Aminopyrimidine derivatives for use as modulators of kinase activity
BR112013013695A2 (pt) derivado de pirazol
DK2513107T3 (da) Heteroaromatiske phenylimidazol-derivater som pde10a-enzyminhibitorer
DK2513106T3 (da) Heteroaromatiske aryltriazol-derivater som pde10a-enzyminhibitorer
EP3083622A4 (en) Maleimide derivatives as modulators of wnt pathway
EP2560655A4 (en) SUBSTITUTED PYRIMIDINES
DK2571843T3 (da) Forbedret fremstilling af chalcon-derivater
EP2603490A4 (en) NEW TRPV3 MODULATORS
CU24142B1 (es) Composiciones nasales de vitamina b12
PT2774612T (pt) Formulações de 4-metilpirazol
DK2407155T3 (da) Formuleringer af inecalcitol
DK2566849T3 (da) 8-Hydroxy-quinolinderivater
FR2957260B1 (fr) Nouvelle formulation dermocorticoide
BR112013013207A2 (pt) derivados de pirimidina
IT1401153B1 (it) Formulazioni di lisozima gelificato